PallardFVMarkovicJGarcaJLViaJ
In contrast, applications like solar lights need low C ratings for longer discharge times
Gonzlez LF, Acua E, Arellano G, Morales P, Sotomayor P, Oyarzun-Ampuero F, et al
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
This page treats both formats as research-context references, not personal use guidance
Due to their vastly different receptor binding profiles and systemic effects, they are not interchangeable